https://www.mayo.edu/research/clinical-trials/cls-20423882
A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in...
Learn more about services at Mayo Clinic.
a studyefficacy of
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.564108/full
Frontiers | Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
BCL-2 family proteins primarily work as a programmed cell death regulator, whereby multiple interactions between them determine cell survival. This explains ...
clinical review
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-navitoclax-with-ruxolitinib-for-myelofibrosis-transform-1
A trial of navitoclax with ruxolitinib for myelofibrosis (TRANSFORM 1)
This trial is combining navitoclax with ruxolitinib for intermediate 2 or high risk myelofibrosis.
a trialnavitoclaxruxolitinibmyelofibrosistransform
https://www.dana-farber.org/clinical-trials/21-714
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination...
Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose...
https://www.ebi.ac.uk/chebi/CHEBI:94128
navitoclax (CHEBI:131174)
navitoclaxchebi